Breaking News
Sort by:
Date
Top Post
CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM
CNS Pharmaceuticals, a biopharmaceutical company specializing in the development of novel treatments for primary and […]
European Medicines Agency accepts Marketing Authorization Application for lecanemab as treatment for early Alzheimer's disease
BioArctic AB‘s partner Eisai have announced that the European Medicines Agency (EMA) has accepted a […]
Eisai Submits Marketing Application for lecanemab for Alzheimer's
BioArctic AB’s partner Eisai announced today that Eisai has submitted a marketing authorization application for […]
- ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Read more
- Superior HealthPlan and eFamilyCare Expand Partnership to Support Medicaid Members and Caregivers in Texas Read more
- Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform Read more
- FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate Read more
- $25 Million Gift to Penn Medicine and Children’s Hospital of Philadelphia Establishes Center for Epilepsy and Neurodevelopmental Disorders Read more